Chronic Spontaneous Urticaria Therapeutics Market Size in the 7MM was ~USD 2200 Million in 2023, it is expected to grow by 2034 and estimated DelveInsight

DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Chronic Spontaneous Urticaria Market by downloading the comprehensive report from DelveInsight @ Chronic Spontaneous Urticaria Treatment Market Size [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Spontaneous Urticaria Market

* In December 2024:- Celldex Therapeutics - The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
* In December 2024:- Novartis Pharmaceuticals - The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
* According to DelveInsight's epidemiology model, the total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases were approximately 2.8 million among the 7MM in 2023 which is expected to change during the forecast period (2024-2034).
* In the US, there were approximately 521 thousand Chronic Spontaneous Urticaria Diagnosed Prevalent Cases in 2023 which was nearly 19% of the total 7MM.
* Among the EU4 and the UK, Germany had the highest Chronic Spontaneous Urticaria Diagnosed Prevalent Cases in 2023 with approximately 327 thousand cases followed by France with nearly 255 thousand cases. On the other hand, Spain accounted for the least with approximately 163 thousand cases.
* In 2023, Japan accounted for the highest Chronic Spontaneous Urticaria Diagnosed Prevalent Cases with approximately 1 million cases.
* Among the age-specific diagnosed prevalent cases of chronic spontaneous urticaria in the US, there were approximately 47 thousand, 80 thousand, 72 thousand, 81 thousand, 86 thousand, and 156 thousand cases in the age groups



This release was published on openPR.